{"entity":{"id":"mablink-bioscience","kind":"company","name":"Mablink Bioscience","aka":[],"tldr":"Mablink Bioscience, from Lyon, invented PSARlink, a water-soluble polysarcosine linker that hides the greasy cell-killing payload so an antibody can carry a higher load of drug molecules and still stay stable in the blood. Eli Lilly bought the company in 2023, before any of its medicines had reached patients.","summary":"Mablink Bioscience was a preclinical Lyon-based biotech whose PSARlink platform uses a hydrophilic polysarcosine linker arm to mask hydrophobic cytotoxic payloads, enabling homogeneous, plasma-stable antibody-drug conjugates with high drug-to-antibody ratios while preserving pharmacokinetics and tolerability; PSARlink ADCs showed an improved therapeutic index in animal models. The company was funded by a 2021 seed round led by Elaia Partners with UI Investissement and Relyens Innovation Santé, and a July 2022 Series A led by Sofinnova Partners and Mérieux Equity Partners. On 18 October 2023 Mablink announced an agreement to be acquired by Eli Lilly, subject to French Ministry of the Economy approval; terms were not disclosed. Lilly's fourth-quarter 2023 results list the acquisition of Mablink as completed in that quarter. The company domain now redirects to lilly.com.","asOf":"2026-10-29","links":[{"label":"Official website","url":"https://www.lilly.com/"},{"label":"Acquisition announcement (BioSpace copy)","url":"https://www.biospace.com/mablink-bioscience-enters-an-agreement-to-be-acquired-by-lilly"},{"label":"Lilly Q4 2023 results listing the completed acquisition (SEC exhibit)","url":"https://www.sec.gov/Archives/edgar/data/59478/000005947824000032/q423lillysalesandearningsp.htm"}],"tags":[],"related":[],"cancers":[],"sections":["adcs"],"technologies":["adc"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["mablink.com redirects to lilly.com, recorded as the website. Series A amount (reported elsewhere as EUR 31 million) not stated in the fetched source and omitted. GlobeNewswire original could not be fetched. Completion in the fourth quarter of 2023 is taken from Lilly's results release filed with the SEC on 6 February 2024, which names the company Mablink Biosciences SAS; the exact closing date is not stated there."],"hq":"Lyon","country":"FR","companyType":"biotech","website":"https://www.lilly.com/","stage":"acquired","investors":["sofinnova-partners"],"funding":[{"round":"Seed","year":2021,"source":"https://www.biospace.com/mablink-bioscience-enters-an-agreement-to-be-acquired-by-lilly","note":"Led by Elaia Partners; amount not stated in the fetched release copy"},{"round":"Series A","year":2022,"source":"https://www.biospace.com/mablink-bioscience-enters-an-agreement-to-be-acquired-by-lilly","note":"July 2022, led by Sofinnova Partners and Mérieux Equity Partners; amount not stated in the fetched release copy"},{"round":"Acquisition","year":2023,"source":"https://www.biospace.com/mablink-bioscience-enters-an-agreement-to-be-acquired-by-lilly","note":"Agreement announced 18 October 2023; terms not disclosed"}],"acquiredBy":"eli-lilly"},"route":"/companies/mablink-bioscience/","neighbours":{"section":[{"id":"adcs","kind":"section","name":"Antibody-Drug Conjugates","route":"/fronts/adcs/"}],"technology":[{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"}],"company":[{"id":"eli-lilly","kind":"company","name":"Eli Lilly (incl. Loxo)","route":"/companies/eli-lilly/"},{"id":"sofinnova-partners","kind":"company","name":"Sofinnova Partners","route":"/companies/sofinnova-partners/"}]}}